Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SYNTEX PHARMACEUTICAL OPERATIONS AND IS PAUL FREIMAN

Executive Summary

SYNTEX PHARMACEUTICAL OPERATIONS AND IS PAUL FREIMAN, who was named by company to run the drug business as part of a management reorganization in the wake of the departure of Syntex President Richard Rogers. "Paul E. Freiman will become exec VP of Syntex, responsible for managing the worldwide pharmaceuticals and agribusiness operations," the firm said in an Oct. 30 press release. Freiman, who will also be a candidate for election to Syntex' board at the annual shareholder meeting Dec. 13, will assume responsibility for the drug business from Ian McDonald, who retired in August. In addition, Corporate VP and President of Syntex Diagnostics Div. Thomas Gutshall will become senior VP of Syntex responsible for management of the diagnostics div., the chemical operations and technical services group as well as Syntex Dental Products. The release notes that both Gutshall and Freiman will report directly to Chairman and CEO Albert Bowers, PhD, in their new roles. Together, they will share some of the responsibilities held by Rogers, who is retiring at the end of 1985. At that time Bowers will assume the additional title of president ("The Pink Sheet" Sept. 30, In Brief). Named to the newly created positions of vice chairman of the Syntex board of directors are John Fried, PhD, and Hans Wolf. The release notes that Fried will also continue as president of Syntex Research and Wolf will continue as chief administrative officer. In addition, Alan Jarrett, senior VP of human resources will continue as acting president of Syntex Ophthalmics. "I am confident that this restructuring of our management team will place us in a strong position to meet the challenges and opportunities we see ahead, especially as we prepare to introduce potentially major new pharmaceutical products," Bowers said. A registered pharmacist and a Syntex employee for the last 27 years, Frieman was most recently senior VP human pharmaceuticals, responsible for the company's worldwide drug business, which accounts for roughly two-thirds of corporate sales. Prior to that he served as VP, western hemisphere-Pacific region. Gutshall served as president of Syva, the largest subsidiary of the Syntex Diagnostics Div., from 1981 until recently. Before that he held the position of group VP Syntex U.S.A., in charge of engineering, production technical services and pharmaceutical chemical manufacturing.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS009198

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel